TY  - GEN
AU  - von Minckwitz,Gunter
AU  - Puglisi,Fabio
AU  - Cortes,Javier
AU  - Vrdoljak,Eduard
AU  - Marschner,Norbert
AU  - Zielinski,Christoph
AU  - Villanueva,Cristian
AU  - Romieu,Gilles
AU  - Lang,István
AU  - Ciruelos,Eva
AU  - De Laurentiis,Michele
AU  - Veyret,Corinne
AU  - de Ducla,Sabine
AU  - Freudensprung,Ulrich
AU  - Srock,Stefanie
AU  - Gligorov,Joseph
TI  - Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
SN  - 1474-5488
PY  - 2015///0127
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Follow-Up Studies
KW  - Genes, erbB-2
KW  - genetics
KW  - Humans
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Invasiveness
KW  - pathology
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Patient Selection
KW  - Remission Induction
KW  - methods
KW  - Retreatment
KW  - Survival Analysis
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(14)70439-5
ER  -